恒瑞医药

Hengrui Pharma reported Q1–Q3 2025 revenue of RMB 23.2B (+14.85% YoY) and net profit of RMB 5.75B (+24.5% YoY). The solid performance was driven by continuous momentum in homegrown innovation and expanding global partnerships, accelerating the delivery of cutting-edge therapies to patients worldwide. Read the full press release: https://bit.ly/48XzIJ3 #FinancialResults #RevenueGrowth #Hengrui

Hengrui Pharma Employee Value Propositions Officially Released! Shining Together! Steven Hu, Vice President and Chief Technology Officer of Hengrui Pharma, remarked: "Choosing Hengrui means stepping onto an international stage where scientific ideals are transformed into global therapeutic solutions. Joining Hengrui is not only the beginning of a career, but also an opportunity to align personal aspirations with the future of China's pharmaceutical industry." Innovate globally, shine with Hengrui.

Hengrui Pharma participated in #ESMO2025 in Berlin, marking a new milestone with the debut of its first exhibition booth. The company also presented 46 oncology studies across 14 innovative programs — including 9 oral presentations and 4 late-breaking abstracts. For the tenth consecutive year, Hengrui shared landmark clinical data and engaged with global experts through a series of academic exchanges — further advancing the international presence of innovation in cancer research and care. Read the full press release: https://bit.ly/4hhPYGK #ESMO2025 #Oncology #ClinicalData #Innovation #Hengrui

Hengrui Pharma Employee Value Propositions Officially Released! Shining Together! Meade Zhang, Vice President and Chief Human Resources Officer of Hengrui Pharma, shared: “At Hengrui, personal growth goes hand in hand with the company’s progress. We provide clear career pathways and a future filled with possibilities, ensuring that every effort is recognized and rewarded.”  Innovate globally, shine with Hengrui.

Hengrui Pharma Employee Value Propositions Officially Released! Shining Together! Steven Huo, Vice President of Hengrui Pharma and General Manager of the Biopharmaceutical BU, remarked: "Hengrui's leadership team brings both forward-looking vision and strong execution. With a clear strategic roadmap, they guide our employees with determination and foster true synergy between individual growth and the company's overall goals." Innovate globally, shine with Hengrui.

Hengrui Pharma Employee Value Propositions Officially Released! Shining Together! Frank Jiang, Executive Vice President and Chief Strategy Officer of Hengrui Pharma, shared: “At Hengrui, we place equal emphasis on independent R&D and open collaboration, propelling China‘s pharmaceutical industry onto the global stage. Here, our employees can transform their scientific hypotheses and innovative ideas into reality. Looking ahead, we will further deepen our collaborations with global partners to accelerate the translation of innovation and bring benefits to more patients worldwide." Innovate globally, shine with Hengrui.

Hengrui Pharma Employee Value Propositions Officially Released! Shining Together! Lianshan Zhang, Executive Vice President of Hengrui Pharma, noted: “Innovation is the very soul of Hengrui. With sustained R&D investment and a forward-looking global strategy, we have advanced from ‘following’ to ‘keeping pace’ and now to ‘leading the way in certain areas’. At Hengrui, every scientific hypothesis can be tested, and every innovative idea has the opportunity to come to life.“ Innovate globally, shine with Hengrui.

Hengrui Pharma Employee Value Propositions Officially Released! Shining Together! Jo Feng, President of Hengrui Pharma, shared: “At Hengrui, 'innovation' and ‘globalization' are at the core of our strategy. By building a diverse and inclusive global organization with a clear strategic roadmap, we attract exceptional talents who share our vision. As an industry leader rooted in China, we are committed to becoming a world-class multinational pharmaceutical group and bringing innovative medicines to patients around the world.“ Innovate globally, shine with Hengrui！

Hengrui Pharma Employee Value Propositions Officially Released! Shining Together! At Hengrui, we are committed to creating an environment where every employee can thrive: Our forward-looking strategy and trusted brand support your career ambitions; Our innovation engine and strong pipeline amplify your professional value; Our reliable leadership team helps unlock your full potential; Our diverse career opportunities accelerate your personal growth. Innovate globally, shine with Hengrui！

Hengrui Pharma has entered into an exclusive license agreement with Glenmark Specialty, a wholly-owned subsidiary of Glenmark Pharmaceuticals, for our HER2-targeting antibody drug conjugate (ADC), Trastuzumab Rezetecan (SHR-A1811). The agreement grants Glenmark worldwide rights, excluding the U.S., Canada, Europe, Japan, greater China, Russia, and select Central Asia countries, and includes an $18M upfront payment, up to $1.093B in milestones, and sales-based royalties. This partnership strengthens Hengrui’s global #ADC strategy with the goal of broadening access to innovative cancer therapies for patients worldwide.  Read the full press release: http://prn.to/46nMLSc #oncology